PsyBio Therapeutics Corp.
PSYBF
$0.00
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -33.33% | -96.58% | -96.58% | -96.29% | -96.70% |
| Gross Profit | 33.33% | 96.58% | 96.58% | 96.29% | 96.70% |
| SG&A Expenses | -60.76% | -50.60% | -43.16% | -13.93% | 40.93% |
| Depreciation & Amortization | 50.00% | 300.00% | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -60.92% | -57.36% | -49.99% | -32.91% | 1.17% |
| Operating Income | 60.92% | 57.36% | 49.99% | 32.91% | -1.17% |
| Income Before Tax | 62.58% | 58.98% | 55.66% | 37.54% | 8.11% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 62.58% | 58.98% | 55.66% | 37.54% | 8.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 62.58% | 58.98% | 55.66% | 37.54% | 8.11% |
| EBIT | 60.92% | 57.36% | 49.99% | 32.91% | -1.17% |
| EBITDA | 4.07% | -176.70% | -- | -- | -- |
| EPS Basic | 63.76% | 59.53% | 57.98% | 52.73% | 37.12% |
| Normalized Basic EPS | 54.49% | 52.58% | 45.32% | 59.88% | 42.61% |
| EPS Diluted | 63.76% | 59.53% | 57.98% | 52.73% | 37.12% |
| Normalized Diluted EPS | 54.49% | 52.58% | 45.32% | 59.88% | 42.61% |
| Average Basic Shares Outstanding | 6.18% | 2.32% | 4.68% | 27.68% | 51.35% |
| Average Diluted Shares Outstanding | 6.18% | 2.32% | 4.68% | 27.68% | 51.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |